Perivascular epitheloid cell tumors (PEComas) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors other available therapies have limited benefit. Preclinical evidences showed a crosstalk between the mTOR pathway and estrogen receptor signalling. This provided a rationale for adding an anti-estrogen treatment in female patients becoming resistant to mTOR inhibitors.
Addition of anti-estrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors
Sbaraglia, Marta;Dei Tos, Angelo Paolo;
2020
Abstract
Perivascular epitheloid cell tumors (PEComas) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors other available therapies have limited benefit. Preclinical evidences showed a crosstalk between the mTOR pathway and estrogen receptor signalling. This provided a rationale for adding an anti-estrogen treatment in female patients becoming resistant to mTOR inhibitors.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
